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Abstract: 
The structurally diverse nature of the 1,2-diphenylethylamine template 
provides access to a range of substances for drug discovery work but some 
have attracted attention as ‘research chemicals’. The most recent examples 
include diphenidine, i.e. 1-(1,2-diphenylethyl)piperidine and 2-
methoxydiphenidine, i.e.  1-[1-(2-methoxyphenyl)-2-
phenylethyl]piperidine (MXP, methoxyphenidine, 2-MXP) that have been 
associated with uncompetitive N-methyl-D-aspartate (NMDA) receptor 
antagonist activity. Challenges encountered during chemical analysis 
include the presence of positional isomers. Three powdered samples 
suspected to contain 2-MXP were obtained from three Internet retailers in 
the United Kingdom and subjected to analytical characterization by gas-, 
and high performance liquid chromatography (GC-, HPLC) coupled to 
various forms of mass spectrometry (MS). Nuclear magnetic resonance 
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spectroscopy, infrared spectroscopy and thin layer chromatography were 
also employed. This was supported by the synthesis of all three isomers 
(2-, 3- and 4-MXP) that were obtained from two different synthetic routes. 
The analytical data obtained for the three purchased samples were 
consistent with the synthesized 2-MXP standard. The differentiation 
between the isomers was possible. Distinct stability differences were 
observed for all three isomers during in-source collision-induced 
dissociation of the protonated molecule when employing detection under 
HPLC selected-ion monitoring detection, which added to the ability to 
differentiate between them. Furthermore, the analysis of a 2-MXP tablet by 
matrix assisted inlet ionization Orbitrap mass spectrometry confirmed that 
it was possible to detect the protonated molecule of 2-MXP directly from 
the tablet surface following addition of 3-nitrobenzonitrile as the matrix. 
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Abstract 
 
The structurally diverse nature of the 1,2-diphenylethylamine template provides 
access to a range of substances for drug discovery work but some have attracted 
attention as ‘research chemicals’. The most recent examples include diphenidine, i.e. 
1-(1,2-diphenylethyl)piperidine and 2-methoxydiphenidine, i.e.  1-[1-(2-
methoxyphenyl)-2-phenylethyl]piperidine (MXP, methoxyphenidine, 2-MXP) that 
have been associated with uncompetitive N-methyl-D-aspartate (NMDA) receptor 
antagonist activity. Challenges encountered during chemical analysis include the 
presence of positional isomers. Three powdered samples suspected to contain 2-
MXP were obtained from three Internet retailers in the United Kingdom and subjected 
to analytical characterization by gas-, and high performance liquid chromatography 
(GC-, HPLC) coupled to various forms of mass spectrometry (MS). Nuclear magnetic 
resonance spectroscopy, infrared spectroscopy and thin layer chromatography were 
also employed. This was supported by the synthesis of all three isomers (2-, 3- and 
4-MXP) that were obtained from two different synthetic routes. The analytical data 
obtained for the three purchased samples were consistent with the synthesized 2-
MXP standard. The differentiation between the isomers was possible. Distinct 
stability differences were observed for all three isomers during in-source collision-
induced dissociation of the protonated molecule when employing detection under 
HPLC selected-ion monitoring detection, which added to the ability to differentiate 
between them. Furthermore, the analysis of a 2-MXP tablet by matrix assisted inlet 
ionization Orbitrap mass spectrometry confirmed that it was possible to detect the 
protonated molecule of 2-MXP directly from the tablet surface following addition of 3-
nitrobenzonitrile as the matrix. 
 
Keywords: 1,2-diphenylethylamines; diphenidine; ‘research chemicals’; new 
psychoactive substances; methoxyphenidine   
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Introduction 
 
The 1,2-diphenylethylamine analog 1-[1-(2-methoxyphenyl)-2-phenylethyl]piperidine 
(2-MeO-diphenidine, MXP, methoxyphenidine, 2-MXP) (Figure 1A) has attracted 
attention as a ‘research chemical’ and is suspected to share some 
psychopharmacological features that are also associated with ‘dissociative 
anaesthetics’, such as ketamine, 1-(1-phenylcyclohexyl)piperidine (PCP) and other 
uncompetitive N-methyl-D-aspartate (NMDA) receptor antagonists.[1] The preparation 
of 2-MXP and a number of analogs originated from medicinal chemistry research into 
the association between NDMA receptor antagonism and neuroprotection[2] The 
availability of substances originally explored during drug discovery related research 
efforts from Internet retailers as ‘research chemicals’ has moved this substance into 
the arena of new psychoactive substances (NPS).[3] In addition, recently published 
case reports described the detection of 2-MXP and its association with acute PCP-
type toxicity[4] and deaths.[5]  
Detailed information on pharmacodynamic properties of 2-MXP remains to be 
uncovered. Binding experiments, based on crude whole rat brain membrane 
preparations using 1 nM [3H]-TCP as the radioligand, revealed involvement of the 
NMDA receptor and indicated distinct differences in affinity under the conditions 
studied. For example, whereas 2-MXP and 3-MXP (Figure 1B) yielded apparent Ki 
values of 32 nM and 26 nM, respectively, a significant loss in affinity was observed 
with the para-substituted 4-MXP isomer (Ki = 8100 nM). In comparison, 1-[1-
(thiophen-2-yl)cyclohexyl]piperidine (TCP), PCP and 2-chlorodiphendine gave Ki 
values of 20 nM, 96 nM and 0.19 nM, respectively.[2] The closely related 1-(1,2-
diphenylethyl)piperidine (diphenidine) (Figure 1A) also appeared on the ‘research 
chemicals’ market before 2-MXP was introduced and both appear to be psychoactive 
in humans.[1] There are indications that diphenidine displays stereoselective 
differences in a number of assays[2,6] but similar data on the 2-MXP enantiomers 
appear to be unavailable. Diphenidine has recently been shown to reduce NMDA-
mediated field excitatory postsynaptic potentials in rat hippocampal slices, which 
confirmed the impact of diphenidine on synaptic transmission.[7] Although it seems 
conceivable that 2-MXP may have similar properties, further work is warranted to 
explore the extent of this possibility.  
The 1,2-diphenylethylamine structural template provides access to a range of 
substances with various properties including bronchodilation[8] and analgesic 
activity.[9,10] The synthetic opioid analgesic 1-cyclohexyl-4-(1,2-
diphenylethyl)piperazines (MT-45, Figure 1A) has also been encountered as a 
‘research chemical’ and ‘legal opioid’. It has recently been associated with a range of 
fatal and non-fatal intoxications, which led to a risk assessment procedure that was 
carried out under the auspices of European Monitoring Centre for Drugs and Drug 
Addiction (EMCDDA).[10,11] Interestingly, (R)-1-(2-(2-ethoxyphenyl)-1-
phenylethyl)piperazine (PF-526014, Figure 1A) and closely related analogs were 
shown to behave as dual serotonin and noradrenaline reuptake inhibitors with good 
selectivity over dopamine inhibition. The lipophilic nature associated with some 
particular analogs also demonstrated a range of off-target effects associated with 
other biological targets.[12-16] Whether these particular analogs are available as 
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‘research chemicals’, however, is not known.  
In situations where reference material is not always available when new 
psychoactive substances are encountered for the first time, challenges can arise 
when approaching the ability to correctly identify these analogs. The availability of 2-
MXP as a ‘research chemical’ and the presence of three positional isomers 
associated with the phenyl ring raised questions about the ability to differentiate 
between them. The present study reports on the analysis of three powdered 2-MXP 
samples sold on the Internet in the United Kingdom. This was supported by the 
analytical characterization of all three isomers (2-, 3- and 4-MXP) that were obtained 
from two independent synthetic routes (Figures 1B/1C). In addition, the analysis of a 
2-MXP tablet, also obtained from a UK-based vendor, was carried out using matrix 
assisted inlet ionization Orbitrap mass spectrometry to assess the applicability of this 
technique with minimal sample preparation.  
 
Experimental 
 
Materials 
 
For synthesis procedure 1, starting materials, reagents and HPLC-grade solvents 
were obtained from Sigma-Aldrich (St. Louis, MO, USA) except for benzyl bromide 
99% (Lancaster synthesis, NH, USA) and CDCl3 100%, 99.96 atom % D with 0.03 % 
(v/v) TMS Aldrich (St. Louis, MO, USA). Flash column chromatography was 
conducted on silica gel 230-400 Mesh, 60 Å, obtained from Sigma Aldrich. Melting 
point range were obtained using a DigiMelt A160 SRS melting point apparatus 
(Stanford Research Systems, Sunnyvale, CA, USA) at a ramp rate of 2 °C/min and 
are uncorrected. For synthesis procedure 2, starting materials, reagents and solvents 
were mostly obtained from Sigma Aldrich (Arklow, Co. Wicklow, Ireland) except for 2- 
and 4-methoxybenzoyl chloride and N,O-dimethylhydroxylamine, which were 
obtained from TCI – Tokyo Chemical Industry Co. Ltd, Tokyo, Japan. LC-MS grade 
solvents were obtained from Fisher Scientific (Dublin, Ireland). 3-Nitrobenzonitrile (3-
NBN), 99% purity, was purchased from TCI America (Portland, OR). Microscope 
cover glasses were purchased from VWR International (Suwanee, GA, USA). Three 
samples, advertised as 2-methoxydiphenidine (2-MXP), were purchased from three 
different online vendors based in the United Kingdom. A photograph of one 
representative product is shown in the supplemental information. A tablet advertised 
to contain 2-MXP was also obtained from a UK based ‘research chemical’ vendor. 
The oval-shaped tablet (259.1 mg, see supplemental data for picture) had a single 
score across the center. Quantitative information was not provided by the supplier.  
 
Syntheses  
 
Synthesis procedure 1 (Figure 1B) 
 
1-[1-(2-Methoxyphenyl)-2-phenylethyl]piperidine (2-MeO-diphenidine, 2-MXP) 
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To a dry round bottom flask containing 40 mL dry acetonitrile (4 Å molecular sieves) 
was added zinc powder (61.2 mmol, 4.0 g), benzyl bromide  (6.72 mol, 0.8 mL), and 
trifluoroacetic acid (5.38 mmol, 0.625 mL). The solution was stirred under argon at 
room temperature for 15 minutes. The remaining benzyl bromide (49.9 mmol, 5.94 
mL), piperidine (23.5 mol, 2.39 mL) and 2-methoxybenzaldehyde (22.0 mmol, 3.0 g) 
were added with vigorous stirring under argon. After approximately 1 hour the 
reaction was found to be complete. The reaction was quenched with a 2 N potassium 
hydroxide solution (200 mL) and extracted with dichloromethane (3 x 100 mL). The 
pooled organic extracts were gravity filtered through a small silica plug to remove 
insoluble material. The organic phase was washed with saline, dried with anhydrous 
magnesium sulfate and concentrated under vacuum to give an amber oil. This crude 
base was purified via flash column chromatography over silica gel with a mobile 
phase of hexanes to give 4.1 g of colorless oil (63.2 % yield). For the formation of the 
hydrochloride salt, the purified freebase was dissolved in 20 mL acetone and titrated 
to pH 1 with concentrated HCl solution. The solvent was then reduced under a 
stream of warm air. Acetone was added and evaporation continued until all residual 
acid and H2O were removed. Following a number of repeated cycles, a white 
crystalline solid was obtained. The solids were washed with ethyl acetate and dried 
in an oven at 60 °C. The crystals were then recrystallized by dissolving in 3 mL warm 
EtOH and diluting to 50 mL Et2O and storing at 0 °C overnight. Solids were collected, 
via decanting of the solvent, washed with ethyl acetate (2 x 5 mL) and dried in an 
oven at 60 °C. This was repeated for a total of 3 times to give a white crystalline solid 
(m.p. 171.5–172.6 °C). HR-ESIMS: observed m/z 296.2005 (theory [M + H]+: 
C20H26NO
+ m/z 296.2009). 1H and 13C NMR data are shown in Table 1. 
 
1-[1-(3-Methoxyphenyl)-2-phenylethyl]piperidine (3-MeO-diphenidine, 3-MXP) 
 
The reaction was carried out as described above using 3-methoxybenzaldehyde 
instead. Melting point of hydrochloride salt: 169.0–170.5 °C. HR-ESIMS: observed 
m/z 296.2005 (theory [M + H]+: C20H26NO
+ m/z 296.2009). 1H and 13C NMR data are 
shown in Table 1. 
 
1-[1-(4-Methoxyphenyl)-2-phenylethyl]piperidine (4-MeO-diphenidine, 4-MXP) 
 
The reaction was carried out as described above using 4-methoxybenzaldehyde 
instead. Melting point of hydrochloride salt: 93.0–94.0 °C (MeOH/Et2O) (lit. 132 – 135 
°C (toluene)[17]). HR-ESIMS: observed m/z 296.2004 (theory [M + H]+: C20H26NO
+ m/z 
296.2009). 1H and 13C NMR data are shown in Table 1. 
 
Synthesis procedure 2 (Figure 1C) 
 
1-[1-(2-Methoxyphenyl)-2-phenylethyl]piperidine (2-MeO-diphenidine, 2-MXP) 
 
Triethylamine (Et3N) (21.2 g, 30 mL, 210 mmol) was added to a mixture of 2-
methoxybenzoyl chloride (50.0 mmol, 8.53 g), N,O-dimethylhydroxylamine (65.5 
mmol, 4.0 g) and catalytic amounts of 4-dimethylaminopyridine (DMAP) (100 mg) in 
dichloromethane (100 mL) and the resulting mixture was stirred for 14 hours. Water 
was added and the resulting mixture was extracted with ethyl acetate (3 x 200 mL). 
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The organic fractions were combined, dried with MgSO4, filtered and concentrated to 
give the desired Weinreb amide (7.74 g). To a solution of this amide (20.5 mmol, 4 g) 
in tetrahydrofuran (30 mL) at 0 oC was added benzylmagnesium chloride (20 mL) 
and the resulting mixture was stirred overnight. The reaction was quenched with 5% 
HCl and extracted with diethyl ether (3 x 200 mL). The organic fractions were 
combined, dried with MgSO4, filtered and concentrated to give the desired ketone 
(10.42 g). A mixture of this ketone (26.5 mmol, 6 g), ammonium acetate (700 mmol, 
56 g), powdered 3 Å molecular sieves (16.8 g) in methanol (360 mL) was stirred at 
room temperature for one hour. To this mixture, 1.6 g of sodium cyanoborohydride 
(25 mmol) in 24 mL THF was added and the mixture was stirred overnight. The 
reaction was then filtered over a pad of celite and rinsed with 200 mL methanol and 
200 mL dichloromethane. The combined filtrates were concentrated and the residue 
dissolved in water. This was made alkaline with 5 M NaOH and extracted with 
dichloromethane (3 x 100 mL). The organic fractions were combined, dried with 
MgSO4, filtered and concentrated to give desired primary amine (5.7 g). 1,5-
Dibromopentane (71 mmol, 16.25 g, 9.6 mL) was added dropwise to a solution of the 
primary amine (21 mmol, 4.7g), potassium carbonate (0.14 mol, 19.5 g) in 
acetonitrile (182 mL) and stirred under nitrogen for 3 days at room temp. The 
potassium salts were removed by filtration, and the filtrate was washed with 
acetonitrile and concentrated yielding crude 2-methoxydiphenidine (MXP) (17.7 g). 
For the formation of the hydrochloride salt, 30 mL of ethereal HCl was added to the 
crude 2-MXP (20 mmol, 6.0 g). The addition of tert.-butyl methyl ether and an 
overnight stirring period followed. The stirring process (trituration) allowed the 2-MXP 
HCl salt to fall out of solution. The mixture was centrifuged, supernatant removed, 
and the solid washed with hexane and dried under vacuum yielding 2-
methoxydiphenidine HCl salt as a white powder (0.434 g, 45% total yield calculated 
from 2-methoxybenzoyl chloride) m.p. 171.0–172.0 oC. HR-ESIMS: observed m/z 
296.1999 (theory [M + H]+: C20H26NO
+ m/z 296.2009). 1H and 13C NMR data are 
shown in Table 1. 
 
1-[1-(3-Methoxyphenyl)-2-phenylethyl]piperidine (3-MeO-diphenidine, 3-MXP) 
 
The reaction was carried out as described above using 3-methoxybenzoyl chloride 
instead yielding 3-methoxydiphenidine HCl salt as a white powder (0.534g, 55% yield 
calculated from 3-methoxybenzoyl chloride) m.p. 142.0-145.5 °C. HR-ESIMS: 
observed m/z 296.1998 (theory [M + H]+: C20H26NO
+ m/z 296.2009). 1H and 13C NMR 
data are shown in Table 1. 
 
1-[1-(4-Methoxyphenyl)-2-phenylethyl]piperidine (4-MeO-diphenidine, 4-MXP) 
 
The reaction was carried out as described above using 4-methoxybenzoyl chloride 
instead yielding 4-methoxydiphenidine HCl salt as a white powder (0.497g, 24% yield 
calculated from 4-methoxybenzoyl chloride) m.p. 88.5-91.0 °C. HR-ESIMS: observed 
m/z 296.1996 (theory [M + H]+: C20H26NO
+ m/z 296.2009). 1H and 13C NMR data are 
shown in Table 1. 
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Instrumentation 
 
Nuclear magnetic resonance spectroscopy 
 
1H (400 MHz) and 13C NMR spectra (100 MHz) were recorded on a Bruker 
Ultrashield 400 plus spectrometer with a 5 mm BBO S1 (Z gradient plus) probe at 
24 °C.  The freebase samples were dissolved in CDCl3 (100% and 99.96% D, 0.03% 
(v/v) TMS) to give approximately 20 mg/mL concentrations. Aliphatic chemical shifts 
were assigned using 1-D and 2-D heteronuclear experiments. Internal chemical shift 
references were TMS (δ = 0.00 ppm) and solvent (δ = 77.0 ppm). The MXP 
standards synthesized using procedure 2 were prepared in deuterated dimethyl 
sulfoxide (DMSO-d6) (20 mg/mL). 
1H (600 MHz) and 13C NMR (100 MHz) spectra 
were recorded on a Bruker AV600 NMR spectrometer using a 5 mm TCI cryoprobe. 
1H NMR spectra were referenced to an external TMS reference at δ= 0 ppm. 
 
Gas chromatography ion trap mass spectrometry 
 
GC-MS data were acquired on a Varian 450-GC gas chromatograph coupled to a 
Varian 220-MS ion trap mass spectrometer (Walnut Creek, CA, USA) and in electron 
(EI) and chemical ionization (CI) full scan mode. Samples (0.5 mg/mL) were 
introduced into a Varian CP-1177 injector (275 ºC) in split mode (1:50) using a CP-
8400 autosampler. The MS Data Review function of the Workstation software, 
version 6.91 was employed for data acquisition. Transfer line, manifold and ion trap 
temperatures were set at 310, 80 and 220 ºC, respectively. Helium was the carrier 
gas (1 mL/min, EFC constant flow mode) and the liquid CI reagent was HPLC grade 
methanol. The default settings for CI ionization parameters (0.4 s/scan) were used: 
CI storage level m/z 19.0; ejection amplitude m/z 15.0; background mass m/z 55; 
maximum ionization time 2000 µs; maximum reaction time 40 ms; target TIC 5000 
counts. An Agilent J&W VF-5ms GC column (30 m × 0.25 mm, 0.25 µm film 
thickness) was used to obtain separation. (Agilent, Cheadle, UK). The temperature 
profile was as follows: start at 130 ºC and held for 1 min followed by an increase to 
280 ºC at 20 ºC/min. This was then held constant for 11.50 min to give a total run 
time of 20.00 min. 
Liquid chromatography electrospray mass spectrometry 
 
LC-MS analyses were performed on an Agilent 1100 system. Separation was 
obtained on a Kinetex phenyl-hexyl column (2.6 µm, 100 x 2.10 mm) Phenomenex 
(Cheshire, United Kingdom). Mobile phase A consisted of 0.1% formic acid in water, 
whereas, mobile phase B consisted of 0.1% formic acid in acetonitrile. The Aligent 
LC-MSD settings were as follows: positive electrospray mode, capillary voltage 3500 
V, drying gas (N2) 12 L/min at 350 
oC, nebulizer gas (N2) pressure 50 psi, SIM m/z 
296 and m/z 211, fragmentor voltage 50 V and 110 V. Samples for LC-MS analysis 
were dissolved in acetonitrile/water (1:1, containing 0.1% formic acid) at a 
concentration of 10 µg/mL. The injection volume was 1 µL, flow rate was 0.2 mL/min 
and the column temperature was 30 oC. The total run time was 35 min. The following 
gradient elution program was used: 0–2 min 15% B, followed by an increase to 20% 
within 20 min, returning to 15% within 35 min. 
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High-resolution electrospray ionization mass spectrometry 
HR-ESI mass spectra were recorded by direct injection into a LTQ Orbitrap 
Discovery (Thermo Fisher, Loughborough, UK). Samples were dissolved in 
acetonitrile/water (1:1, containing 0.1% formic acid) and infused at a rate of 5 µL/min. 
Full accurate high-resolution (30000) mass scans were performed in positive 
electrospray mode. Measured accurate masses were within ± 5 ppm of the 
theoretical masses. The following conditions were used: drying gas (N2) 10 L/min, 
capillary temperature 310 ºC, spray voltage 4 V, capillary voltage 22 V and tube lens 
77 V. The mass calibration procedure was performed in both positive and negative 
mode using solutions containing caffeine, L-methionyl-arginyl-phenylalanyl-alanine 
acetate × H2O (MRFA), Ultramark 1621®, sodium docecyl sulfate and sodium 
taurocholate.  
Thin layer chromatography 
 
Analysis was conducted using TLC silica gel 60 F254 20 x 20 cm aluminium sheets 
(Merck, Germany). The mobile phase used was dichloromethane/methanol (9:1) and 
0.8% ammonia (7N in methanol). All standards and vendor samples were dissolved 
in the mobile phase and vortex mixed before spotting onto the TLC plate. Both UV 
light and modified Dragendorff Ludy-Tenger reagent was used for detection. For this 
purpose, bismuth subcarbonate (1 g), potassium iodide (6 g) and concentrated 
hydrochloric acid (15 mL) were diluted with water to give a final volume of 100 mL. 
 
High-resolution matrix assisted inlet ionization mass spectrometry (MAII-MS) 
 
A Thermo Scientific Exactive™ mass spectrometer (Thermo Fisher Scientific, 
Bremen, Germany) was modified by removing the Ion Max source to expose the inlet 
capillary for sample introduction using glass slides. The trap fill time was set at 1000 
ms to correspond with the 1 s required to achieve a resolution of 100000 (50% 
FWHH, m/z 200). The sheath, auxillary, and sweep gas flow rates, as well as the 
electrospray ionization spray voltage, were set to zero. The inlet capillary 
temperature was set at 70 °C. The capillary, tube lens and skimmer voltages were 
optimized at 30, 60, and 18 V, respectively, and acquisition time was set to 
continuous mode. 
 
Tablet preparation for MAII-MS and NMR analysis 
 
The 3-nitrobenzonitrile (3-NBN) matrix was prepared at a 3 mg/mL concentration with 
acetonitrile/water (1:1) with 0.1% formic acid. For matrix assisted inlet ionization 
experiments on cover glass, 100 ppb of a synthesized 2-MXP standard solution was 
prepared in conjuction with the 3-NBN matrix solution. Onto the cover glass, 1 µL of 
analyte/matrix solution was and allowed to air-dry for 2 minutes. For direct MAII-MS 
analysis, 1 µL of matrix solution was added onto the surface of the 2-MXP tablet and 
allowed to air-dry. In order to obtain structural confirmation, the tablet was split in half. 
One half of the tablet (137.6 mg) was extracted by dissolution in 2 N (3 mL) aqueous 
HCl solution, washed with ethyl acetate (3 x 5 mL), gravity filtered to remove 
insoluble components, made basic with concentrated KOH solution and extracted 
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with ethyl acetate (3 x 5 mL). Organic extractions were pooled, dried with MgSO4 and 
concentrated under a stream of warm air to yield about 15 mg of colorless oil. The oil 
was dried and dissolved in 1 mL CDCl3 for 
1H and 13C NMR analysis. 
 
Results and discussion 
 
The appearance of new psychoactive substances on the market can cause 
difficulties in the ability to identify these materials. Furthermore, increasing 
challenges are encountered when facing the potential presence of various positional 
isomers. The three MXP isomers were synthesized using two alternative routes and 
the implementation of techniques commonly used in a forensic science laboratory 
revealed that differentiation between isomers was possible. It was also confirmed 
that 2-MXP was present in three powdered and one tablet sample obtained from 
online retailers in the United Kingdom. 
 
The preparation of 2-, 3-, and 4-MXP isomers was compared using two synthetic 
routes. Procedure 1 (Figure 1B) was based on a three-component procedure 
published by Le Gall et al. who employed this approach for the preparation of 
diarylmethylamines.[18] The application of this one-step procedure provided a 
convenient route of synthesis of the desired isomers. An alternative synthesis 
procedure 2 (Figure 1C), however, was also explored for its applicability to the 
synthesis of 2-, 3-, and 4-MXP. In this particular case, the Grignard reagent was 
added to the Weinreb amide[19] to give the corresponding ketone intermediate. 
Conversion to the primary amine followed by reaction with 1,5-dibromopentane 
yielded the MXP isomers. The final step of the second procedure, i.e. not requiring 
the use of piperidine as a reagent, has also been successfully implemented for the 
preparation of diphenidine and PCP derivatives.[2,7,20] The purification process used in 
procedure 2 was rapid and thus deemed well suited for the purification step in a high 
throughput forensic science laboratory. It involved the direct conversion of the crude 
freebase to the hydrochloride salt. Addition of ethereal HCl and tert.-butyl methyl 
ether to the crude freebase and stirring overnight afforded the purified HCl salt 
following precipitation from the solution. All three isomers could be distinguished by 
1H and 13C NMR (Table 1).   
 
Analytical features  
 
Three samples labeled to contain 2-MXP were obtained from three different Internet 
providers and analyzed by gas chromatography (GC) ion trap mass (IT) mass 
spectrometry (MS) in electron- (EI) and chemical (CI) ionization modes. A 
comparison with the synthesized reference material is shown in Figure 2 and 
confirmed that all test purchase samples were consistent with the identity of the 2-
MXP isomer as indicated on the product label. The employed GC method did allow 
for the separation of all three isomers as well. Mass spectral data obtained from all 
three isomers are shown in Figure 3. EI-IT mass spectra (Figure 3A−C) displayed a 
comparatively weak abundance of the molecular ion while the corresponding CI-IT 
mass spectra (Figure 3D−F) confirmed the presence of the [M + H]+ without difficulty. 
The structural suggestions for the key ions observed under these conditions are 
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shown in Figure 3 and the mechanisms of formation may be comparable to 
diphenidine. In this case (e.g. under EI conditions), a m/z 174 base peak is observed 
rather than m/z 204 due to the absence of the methoxyl group.[7]  
 
The samples labeled to contain 2-MXP and the MXP standards (procedure 2) were 
also analyzed using an alternative GC-EI quadrupole MS method. The GC method 
used was able to distinguish between all three isomers and baseline separation was 
achieved between each isomer. The retention times were recorded at 19.15 min, 
19.54 min and 19.86 min for 2-MXP, 3-MXP and 4-MXP isomers, respectively. The 
EI mass spectra obtained for each MXP isomer were similar as expected 
(supplemental data). Under EI quadrupole MS conditions, the abundance of the 
molecular ion was also low (supplemental data). All test purchases were found to be 
consistent with the identity of 2-MXP using this alternative method.  
 
HPLC-MS was also utilized for the discrimination of the MXP isomers. Early attempts 
using an Allure® PFP Propyl column failed to resolve the isomers. However, switching 
to a phenyl hexyl column successfully permitted differentiation between isomers. The 
HPLC method achieved baseline separation for the 2-MXP isomer but the 3- and 4-
MXP isomers provided partial separation. Although this appeared suitable for 
identification purposes, distinctive differences in the stability of the protonated 
molecules were also observed. For example, implementation of in-source collision-
induced dissociation (110 V fragmentor voltage) under electrospray ionization single 
quadrupole MS conditions (Figure 4A) revealed that 4-MXP displayed the lowest 
stability, which resulted in the disappearance of [M + H]+ via elimination of piperidine 
and formation of m/z 211. Inspection of the relative abundance values related to the 
product ions also indicated that the 3-MXP isomer appeared to yield the most stable 
protonated molecule. In comparison, 2-MXP was noticed to exhibit a lower stability 
than 3-MXP. Figure 4B depicts the suggested mechanisms of dissociation that may 
account for the differences in stability of the protonated molecules. Elimination of 
piperidine from 4-MXP may give rise to a resonance-stabilized cation that could have 
been the driving force behind the extensive dissociation of [M + H]+. Resonance-
stabilization following dissociation of 3-MXP was considered impossible, in addition 
to the possible formation of a less thermodynamically favored 
bicyclo[4.1.0]heptadienylidene oxonium species (Figure 4B). 2-MXP appeared to be 
less stable than 3-MXP because of the ability to form a resonance-stabilized product 
ion at m/z 211 while the possibility of an ortho-effect, i.e. hydrogen bond interaction 
with the piperidine hydrogen, might have resulted in higher stability than 4-MXP  
 
This differential feature provided the opportunity to obtain further unambiguous 
information when switching the fragmentor voltage settings between 50 V and 110 V, 
respectively. The m/z 296 ([M+H]+) and m/z 211 product ions were investigated using 
the selected ion-monitoring (SIM) mode. At the lower voltage of 50 V, the SIM 
chromatogram at m/z 296 revealed the detection of all three isomers (Figure 5A). 
However, 4-MXP was detected when the m/z 211 product ion was chosen while 3-
MXP remained undetectable and 2-MXP showed low detectability (Figure 5B). At 
higher energies of 110 V, the SIM trace at m/z 296, revealed the detection of 2-MXP 
and 3-MXP isomers only (Figure 5C), which confirmed reduced stability of the 2-MXP 
isomer compared to its 3-MXP counterpart. Consistent with extensive dissociation, 4-
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MXP was not visible in the SIM chromatogram of the protonated molecule. However, 
all three isomers were detected when the dissociated m/z 211 was used instead 
(Figure 5D). For comparison, electrospray ionization triple quadrupole tandem mass 
spectra and high mass accuracy quadrupole time-of-flight tandem mass spectra of all 
three isomers are shown as supplemental information. All three synthesized MXP 
isomers were also separable using thin layer chromatography (TLC) and 
confirmation was obtained that 2-MXP was present in the commercially available 
samples.  The values obtained for the retardation factors of 2-, 3-, and 4-MXP were 
0.57, 0.77, and 0.60, respectively  (supplemental data). It was encouraging to 
observe the facile separation under TLC conditions, which illustrated the value of 
employing a seemingly simplistic method of analysis. This TLC method could be 
advantageous in situations where pressures on time and sampling conditions might 
place limitations on the ability to implement instrumental analysis. 
 
Recent casework involving the detection of 2-MXP in three deaths revealed that the 
differentiation between the three MXP isomers could present challenges on HPLC 
retention time differences alone. It was reported that 2-MXP was separated from the 
3-MXP and 4-MXP but the latter two were observed to co-elute under the conditions 
used. Implementation of the diode array detection system (DAD), however, allowed 
for the differentiation between 3-MXP and 4-MXP due to distinct ultraviolet fullscan 
spectra, which provided evid nce that HPLC-DAD was considered suitable to 
confirm the capability for differentiation.[5] 
 
The implementation of matrix assisted inlet ionization mass spectrometry (MAII-
MS)[21-23] (Figure 6) established that it was possible to detect the protonated molecule 
of 2-MXP directly from the tablet surface (supplemental data) following addition of the 
3-nitrobenzonitrile matrix. The MAI ionization process occurs in the heated inlet 
capillary of the instrument without the assistance of a laser, as, for example required 
for the matrix-assisted laser desorption ionization (MALDI) approach. NMR analysis 
of the extracted material then confirmed the presence of the 2-MXP isomer 
(supplemental data).  
 
The appearance of diphenidine and 2-MXP as commercially available ‘research 
chemicals’ was considered a replacement for methoxetamine. In the UK, market 
introduction of both substances were closely linked to the introduction of legislative 
control of methoxetamine.[1] Closely related compounds have also been detected in 
2008 where a drug seizure obtained from a clandestine laboratory operating in 
Germany revealed the presence of 1,2-diphenylethylamine and the two N-ethyl and 
N-isopropyl analogs. Mass spectral investigations and micro synthesis of several 
additional derivatives have been reported, which illustrated the importance to identify 
these newly emerging substances.[24] A comprehensive investigation of phase I and 
phase II metabolism using both N-alkylated substances in rats has been published 
recently.[25] The need for additional analytical investigations of products suspected to 
contain 1,2-diphenylethylamine derivatives might increase as more information about 
their prevalence of use and availability become accessible.  
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Conclusion 
 
The appearance of newly emerging psychoactive ‘research chemicals’ and their 
recreational use outside controlled settings creates analytical challenges for 
scientists in the forensic, clinical and toxicology fields. The present study 
demonstrated the ability to differentiate between 2-methoxydiphenidine and its two 
positional isomers. The combination of test purchases from online vendors, analytical 
characterization and confirmation by organic synthesis was found to be a useful 
approach for the generation of analytical data that may be of interest to a range of 
stakeholders. The analysis of a 2-MXP tablet by matrix assisted inlet ionization 
Orbitrap mass spectrometry provided the indication that surface analysis from solid 
sample material may be a viable option for forensic analysis, which warrants further 
investigation.   
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Figure captions: 
 
Figure 1. A: Chemical structures of 1,2-diphenylethylamine representatives. 2-
Methoxydiphenidine, diphenidine and MT-45 been encountered as ‘research 
chemicals’. B and C: Synthesis of three MXP isomers via two different routes. 
 
Figure 2. Implementation of gas chromatography ion trap mass spectrometry for the 
analysis of three powdered samples obtained from three UK-based vendors.  
 
Figure 3. Electron (EI) and chemical (CI) ionization ion trap mass spectra obtained 
from introduction by gas chromatography.   
 
Figure 4. A: Electrospray ionization single quadrupole mass spectrum following in-
source collision-induced dissociation at 110 V. B: Suggested mechanisms of 
dissociation that may account for the differences in stability of the protonated 
molecule (3-MXP > 2-MXP > 4-MXP).  
 
Figure 5. Analysis of synthesized MXP isomers using high performance liquid 
chromatography selected ion monitoring (SIM) mass spectrometry with varying 
fragmentor voltages.  
  
Figure 6. Top left: Tablet obtained from an UK-based vendor and sold as 2-MXP. 
Direct analysis was carried out by matrix assisted inlet ionization Orbitrap mass 
spectrometry using 3-nitrobenzonitrile (3-NBN) as the matrix. Top right: mixed matrix 
and 2-MXP reference droplets after air-dry on glass plate. Bottom left: MAII operating 
with samples on cover glass. Bottom right: Direct analysis of 2-MXP tablet and 
confirmation of the protonated molecule by high resolution Orbitrap MS. 
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Table 1. NMR data for the MXP standards freebase (synthesis procedure 1) and hydrochloride salts (synthesis procedure 2) 
2-Methoxydiphenidine 3-Methoxydiphenidine 4-Methoxydiphenidine 
 
 
 
 
 
 
 
Freebase HCl Salt Freebase HCl Salt Freebase HCl Salt 
13
C 
1
H 
13
C 
1
H 
13
C 
1
H 
13
C 
1
H 
13
C 
1
H 
13
C 
1
H 
157.99 (Ar-C; 2’) 7.34 (dd; J = 7.6 Hz, 1.8 
Hz; 1 Ar-H; 6’) 
157.98 (Ar-C; 
2’) 
7.63 (m; 1 Ar-
H; 6’) 
159.13  (Ar-C; 3’) 7.09−7.20 (m; 4 Ar-
H; 3, 4, 5, 5’) 
159.53 (Ar-C; 3’) 7.28 (t; J = 7.9 Hz; 
1 Ar-H, 4) 
158.37 (Ar-C; 4’) 7.19−7.11(m; 3 Ar-H, 3, 4, 5) 160.24 (Ar-C; 
4’) 
7.47 (d; J = 8.7 Hz; 2 
Ar-H; 2’, 6’) 
140.23 (Ar-C; 1) 7.18−7.08 (m; 3 Ar-H; 3, 
5, 4’) 
136.28 (Ar-C; 
1) 
7.36 (dt; J = 
7.4, 2.1 Hz; 1 
Ar-H; 4’) 
141.19 (Ar-C; 1’) 7.04 (dd; J = 8.1, 1.3 
Hz; 2 Ar-H; 2, 6)  
136.77 (Ar-C; 1’) 7.15−7.20 (m; 3 Ar-
H; 2, 6, 2’) 
140.06 (Ar-C; 1) 7.08 (d; J = 8.6 Hz; 2 Ar-H; 2’, 
6’) 
136.82 (Ar-C; 
1) 
7.16-7.19  (m; 2 Ar-H; 
3, 5) 
129.35 (Ar-C; 2,6) 7.08−7.01 (m; 3 Ar-H; 2, 
6, 4) 
130.98 (Ar-C; 
4’) 
7.15 (tr; J = 7.4 
Hz; 2 Ar-H; 3, 
5) 
139.89 (Ar-C; 1) 6.74−6.79 (m; 2 Ar-
H; 4’, 6’) 
133.36 (Ar C; 1) 7.06−7.12 (m; 4 Ar-
H; 3, 5, 4’, 5’) 
131.17 (Ar-C; 1’) 7.02 (dd; J = 7.6, 1.1 Hz; 2 Ar-
H; 2, 6) 
132.35 (Ar-C; 
4) 
7.07−7.13 (m; 3 Ar-H, 
2, 4, 6) 
128.80 (Ar-C; 6’) 6.92 (dt; J = 7.5 Hz; 1.2 
Hz; 1 Ar-H; 5’) 
130.47 (Ar-C; 
6’) 
7.09 (tr; J = 7.4 
Hz; 1 Ar-H; 4) 
129.37 (Ar-C; 2, 
6) 
6.72 (tr; J = 1.6 Hz; 1 
Ar-H; 2’) 
129.98 (Ar-C; 5’) 6.93 (dd; J = 8.2, 
2.1 Hz; 1 Ar-H; 6’) 
129.95 (Ar-C; 2’, 6’) 6.81 (d;  J = 8.6 Hz; 2 Ar-H; 3’, 
5’) 
129.37 (Ar-C; 
2’, 6’) 
6.94 (d; J = 8.7 Hz; 2 
Ar-H; 3’, 5’) 
128.50 (Ar-C;1’) 6.74 (dd; J = 8.3, 1.2 
Hz; 1 Ar-H; 3’) 
128.91 (Ar-C; 
2,6) 
6.97-7.05 (m; 4 
Ar-H; 2, 6, 3’, 
5’) 
128.47 (Ar-C; 5’)  3.78 (s; 3 H; OCH3) 129.41 (Ar-C; 2, 
6) 
4.65−4.69 (m; 1 H; 
C1) 
129.37 (Ar-C; 2, 6) 3.80 (s; 3 H; OCH3) 128.57(Ar-C; 
2, 6) 
4.68−4.72 (m; 1 H; C1) 
127.58 (Ar-C; 3, 5) 4.31 (dd; J = 9.2, 5.7 
Hz; 1 H; C1) 
128.44 (Ar-C; 
3,5) 
4.91-4.96 (m; 1 
H; C1) 
127.79 (Ar-C; 3, 
5)  
3.59 (dd; J = 9.2, 5.3 
Hz; 1 H; C1) 
128.53 (Ar-C; 3, 
5) 
3.75 (s; 3 H, OCH3) 127.86 (Ar-C; 3, 5) 3.59 (dd;  J = 10.0, 5.9 Hz; 1 
H; C1) 
126.72 (Ar-C; 
3, 5) 
3.75 (s; 3 H, OCH3) 
127.47 (Ar-C; 4’) 3.56 (s; 3 H; OCH3) 126.44 (Ar-C; 
5’) 
3.71 (s; 3 H; 
OCH3) 
125.69 (Ar-C; 4) 3.31 (dd; J = 13.3, 
5.3 Hz; 1 H; C2) 
126.76 (Ar-C; 4) 3.72 (dd; J = 13.2, 
3.7 Hz; 1 H; C2) 
125.61 (Ar-C; 4) 3.32 (dd; J = 13.0, 5.9 Hz; 1 
H; C2) 
122.92 (Ar-C, 
1’) 
3.60−3.67 and 3.51-
3.56 (2 x m; 2 H, C2) 
125.39 (Ar-C; 4) 3.26 (dd; J = 13.4, 5.7 
Hz; 1 H; C2) 
120.54 (Ar-C; 
4) 
3.66 (dd; J = 
13.2; 3.3 Hz; 1 
H; C2) 
121.49 (Ar-C; 6’) 3.03 (dd; J = 13.3, 
9.2 Hz; 1 H; C2) 
122.97 (Ar-C; 6’) 3.51 (dd; J = 13.2, 
12.2 Hz; 1 H; C2) 
113.00 (Ar-C; 3’, 5’) 3.02 (dd; J = 13.0, 10.0 Hz; 1 
H; C2) 
114.28 (Ar-C; 
3’, 5’) 
3.68-3.73, 3.44-3.49 
and 2.57-2.65 (3 x m; 
4 H; Cα) 
119.94 (Ar-C; 5’) 2.94 (dd; J = 13.4, 9.2 
Hz; 1 H; C2) 
119.26 (Ar-C; 
1’) 
3.48 (dd; J = 
13.2, 10.7  Hz; 
1 H; C2) 
114.75 (Ar-C; 2’) 2.39−2.53 (m; 4 H; 
Cα) 
116.61 (Ar-C; 2’) 3.74−3.79, 3.36-
3.42 and 2.61−2.71  
(3 x m; 4 H; Cα) 
71.64 (CH; C1) 2.34−2.55 (m; 4 H; Cα) 69.69 (CH; 
C1) 
1.64−1.92 (m; 4 H;  Cβ) 
110.86 (Ar-C; 3’) 2.45 (t; J = 5.3 Hz; 4 H; 
Cα) 
111.90 (Ar-C; 
3’) 
3.68−3.71, 
3.36−3.42, 
2.74−2.83 and 
2.63−2.71 (4 x 
m; 4 H; Cα) 
112.04 (Ar-C; 4’) 1.50−1.71 (m; 4 H; 
Cβ) 
115.02 (Ar-C; 4’) 1.93−2.02 and 
1.77−1.86  (2 x m, 
3 H; Cβ) 
54.64 (CH3; Cc) 1.50−1.71(m; 4 H; Cβ) 55.44 (CH3; 
Cc) 
1.48−1.54 and 1.24-
1.34 (m; 2 H; Cγ) 
62.48 (CH; C1) 1.63−1.46 (m; 4 H, Cβ) 59.13 (CH; C1) 1.91−1.99, 
1.73−1.85 and 
1.64−1.69 (3 x 
m; 3 H; Cβ) 
 
72.26 (CH; C1) 1.40 (quint; J = 5.7 
Hz; 2 H; Cγ) 
70.13 (CH; C1) 1.64−1.70 and 
1.27−1.35 (m; 2 H; 
Cγ) 
51.28 (2xCH2; Cα) 1.38 (quint; J =  5.6 Hz;  2 H; 
Cγ) 
52.01 and 
48.46 (2 x 
CH2; Cα) 
 
55.49 (CH3; Cc) 1.35 (quint; J = 5.8 Hz; 
2 H; Cγ) 
55.78 (CH3; 
Cc) 
1.29−1.38 (m; 2 
H; Cγ) 
55.14 (CH3; Cc)  55.54 (CH3; Cc)  39.21 (CH2; C2)  35.10 (CH2; 
C2) 
 
51.33 (2 x CH2; Cα)  51.89 and 
48.81 (2xCH2; 
Cα) 
 51.44 (2xCH2; Cα)  52.15 and 49.07 
(2xCH2; Cα) 
 26.30 (2xCH2; Cβ)  22.95 (2 x 
CH2; Cβ) 
 
39.24 (CH2; C2)  34.52 (CH2; 
C2) 
 39.19 (CH2; C2)  35.29 (CH2; C2)  24.62 (CH2; Cγ)  21.74 (CH2; 
Cγ) 
 
26.46 (2 x CH2; Cβ)  22.52 and 
22.48 (2xCH2; 
Cβ) 
 26.36 (2xCH2; Cβ)  22.78 (2xCH2; Cβ)      
24.72 (CH2; Cγ)  21.28 (CH2; 
Cγ) 
 24.64 (CH2; Cγ)  21.83 (CH2; Cγ)      
 
Page 17 of 22
http://mc.manuscriptcentral.com/dta
Drug Testing and Analysis
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
  
 
 
Figure 1. A: Chemical structures of 1,2-diphenylethylamine representatives. 2-Methoxydiphenidine, 
diphenidine and MT-45 been encountered as ‘research chemicals’. B and C: Synthesis of three MXP isomers 
via two different routes.  
218x250mm (300 x 300 DPI)  
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Figure 2. Implementation of gas chromatography ion trap mass spectrometry for the analysis of three 
powdered samples obtained from three UK-based vendors.  
262x358mm (300 x 300 DPI)  
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Figure 3. Electron (EI) and chemical (CI) ionization ion trap mass spectra obtained from introduction by gas 
chromatography.    
163x141mm (300 x 300 DPI)  
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Figure 4. A: Electrospray ionization single quadrupole mass spectrum following in-source collision-induced 
dissociation at 110 V. B: Suggested mechanisms of dissociation that may account for the differences in 
stability of the protonated molecule (3-MXP > 2-MXP > 4-MXP).  
291x574mm (300 x 300 DPI)  
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Figure 5. Analysis of synthesized MXP isomers using high performance liquid chromatography selected ion 
monitoring (SIM) mass spectrometry with varying fragmentor voltages.  
163x183mm (300 x 300 DPI)  
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Figure 6. Top left: Tablet obtained from an UK-based vendor and sold as 2-MXP. Direct analysis was carried 
out by matrix assisted inlet ionization Orbitrap mass spectrometry using 3-nitrobenzonitrile (3-NBN) as the 
matrix. Top right: mixed matrix and 2-MXP reference droplets after air-dry on glass plate. Bottom left: MAII 
operating with samples on cover glass. Bottom right: Direct analysis of 2-MXP tablet and confirmation of the 
protonated molecule by high resolution Orbitrap MS.  
106x101mm (300 x 300 DPI)  
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